The pursuit of effective cancer treatments often involves targeting specific molecular pathways that drive tumor growth and survival. The PI3K/Akt/mTOR pathway is a key player in this regard, and selective inhibitors are crucial for developing precise therapies. GSK2636771, a potent and selective inhibitor of PI3K beta, has demonstrated significant promise in preclinical cancer models. NINGBO INNO PHARMCHEM CO.,LTD., a leading supplier of pharmaceutical intermediates, provides this critical compound to researchers worldwide, enabling them to explore its full potential.

GSK2636771, identified by its CAS number 1372540-25-4, is valued for its high selectivity towards the PI3K beta isoform. This selectivity is particularly important in understanding the complex role of PI3K beta in cancers with PTEN deficiencies, a common scenario in many aggressive tumors. Preclinical studies have shown that GSK2636771 can effectively inhibit tumor cell migration and invasion, crucial steps in the metastatic process. Its oral bioavailability also allows for more relevant in vivo assessments, providing valuable data for potential drug development. As a manufacturer based in China, we ensure the high purity and consistent quality of GSK2636771, supporting reliable preclinical research.

Researchers actively seek to buy GSK2636771 to investigate its anti-cancer properties in various cell lines and animal models. The compound's ability to selectively target PI3K beta offers a pathway to develop treatments that are both effective and have a favorable safety profile. NINGBO INNO PHARMCHEM CO.,LTD. is committed to supporting this critical research by ensuring the availability of high-quality GSK2636771. Our dedication to chemical synthesis and providing advanced pharmaceutical intermediates aims to accelerate the discovery of new cancer therapies. We offer competitive pricing for GSK2636771, making it accessible for a wide range of research projects.

The efficacy of GSK2636771 in preclinical settings has paved the way for its investigation in clinical trials, highlighting its therapeutic potential. As a trusted supplier, NINGBO INNO PHARMCHEM CO.,LTD. plays a vital role in this process by delivering a reliable supply of this important pharmaceutical intermediate. Whether you are exploring new treatment paradigms or validating existing hypotheses, our commitment to quality and accessibility for compounds like GSK2636771 remains unwavering. Partnering with a reputable manufacturer ensures that your research is built on a foundation of reliable chemical synthesis.

In summary, GSK2636771 is a highly valuable compound for preclinical cancer research due to its selective PI3K beta inhibition and demonstrated efficacy. NINGBO INNO PHARMCHEM CO.,LTD. is proud to be a key supplier, supporting the scientific community's efforts to develop advanced targeted therapies. We invite researchers to leverage the potential of GSK2636771 and collaborate with us for their specialized chemical needs in the fight against cancer.